The Latest Cardiac and Vascular News
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held […]
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that its Universal Registration Document was […]
A cash position of more than €20 million at the end of 2022, which provides the Company financial visibility until the end of the first half of 2024; A decisive year on the clinical front with the results of the […]
The last patient included in the study has completed the final protocol follow-up visit. The first results of the study will be released before the end of the first half of 2023, after the database is frozen and the statistical […]
TOTUM•854 protects human cells of the vascular wall, particularly against inflammation and oxidative stress, which is key to preventing worsening of high blood pressure. TOTUM•854 also reduces angiotensin I-converting enzyme (ACE1) activity, one of the main modes of action known […]
A decisive year in clinical terms with results expected in the first half of 2023 from the international Phase II/III REVERSE-IT study on TOTUM•63, a plant-based active substance that has already demonstrated metabolic benefits in prediabetic patients in a previous […]
Internationally, the signing of licensing or distribution partnerships with major players in nutrition and healthcare. In France, Valbiotis has chosen to internalize its commercial operations for direct distribution, in order to generate rapid turnover and to ensure an independent and […]
TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study: Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction […]
A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic and operational roadmap for future commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 […]
This randomized, placebo-controlled Phase II clinical study with TOTUM•070 achieved its objective of reducing LDL cholesterol (primary endpoint) and confirmed the very good tolerance of this active substance. As early as 3 months of supplementation, the results showed a significant […]
